Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: In vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737

Leukemia and Lymphoma

Volumn 50, Issue 7, 2009, Pages 1174-1182

  Jayanthan, Aarthi ^a   Howard, Scott C ^b   Trippett, Tanya ^c   Horton, Terzah ^d   Whitlock, James A ^e   Daisley, Lara ^a   Lewis, Victor ^a   Narendran, Aru ^a  

^a ALBERTA CHILDREN'S HOSPITAL   (Canada)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ABT 737; Apoptosis; Bcl 2; Hodgkin lymphoma; Targeted therapeutics

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; APICIDIN; ARSENIC TRIOXIDE; BORTEZOMIB; BUSULFAN; CETUXIMAB; CISPLATIN; CLOFARABINE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; RITUXIMAB; SORAFENIB; SUNITINIB; SURVIVIN; TANESPIMYCIN; VALPROIC ACID; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; GROWTH INHIBITION; HODGKIN DISEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HODGKIN DISEASE; HUMANS; INHIBITORY CONCENTRATION 50; NF-KAPPA B; NITROPHENOLS; PIPERAZINES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; TIME FACTORS;

EID: 68449101811     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902943069     Document Type: Article

References (54)

1. Nishikori M, Uchiyama T. Molecular pathogenesis of Hodgkin lymphoma. Int J Hematol 2006;83:398-403.
2. Felberbaum RS. The molecular mechanisms of classic Hodgkin's lymphoma. Yale J Biol Med 2005;78:203-210.
3. Jost PJ, Ruland J. Aberrant NF-κB signaling in lymphoma: Mechanisms, consequences, and therapeutic implications. Blood 2007;109:2700-2707.
4. Cochet O, Frelin C, Peyron JF, Imbert V. Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. Cell Signal 2006;18:449-455.
5. Tzankov A, Dirnhofer S. Pathobiology of classical Hodgkin lymphoma. Pathobiology 2006;73:107-125.
6. Bai M, Papoudou-Bai A, Horianopoulos N, Grepi C, Agnantis NJ, Kanavaros P. Expression of bcl2 family proteins and active caspase 3 in classical Hodgkin's lymphomas. Hum Pathol 2007;38:103-113.
7. Aktas S, Kargi A, Olgun N, Diniz G, Erbay A, Vergin C. Prognostic significance of cell proliferation and apoptosis-regulating proteins in Epstein-Barr virus positive and negative pediatric Hodgkin lymphoma. Lymphat Res Biol 2007;5:175-182.
8. Spector N, Milito CB, Biasoli I, Luiz RR, Pulcheri W, Morais JC. The prognostic value of the expression of Bcl-2, p53 and LMP-1 in patients with Hodgkin's lymphoma. Leuk Lymphoma 2005;46:1301-1306.
9. Sup SJ, Alemañ y CA, Pohlman B, et al. Expression of bcl-2 in classical Hodgkin's lymphoma: An independent predictor of poor outcome. J Clin Oncol 2005;23:3773-3779.
10. Kim LH, Nadarajah VS, Peh SC, Poppema S. Expression of Bcl-2 family members and presence of Epstein-Barr virus in the regulation of cell growth and death in classical Hodgkin's lymphoma. Histopathology 2004;44:257-267.
11. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002;100:3935-3941.
12. van Spronsen DJ, Peh SC, Vrints LW, van Imhoff GW, Poppema S. Clinical drug-resistant nodular sclerosing Hodgkin's lymphoma is associated with decreased bcl-2 expression in the surrounding lymphocytes and with increased bcl-2 expression in the Reed-Sternberg cells. Histopathology 2000; 37:420-426.
13. Kanavaros P, Stefanaki K, Vlachonikolis J, et al. Expression of p53, p21/ waf1, bcl-2, bax, Rb and Ki67 proteins in Hodgkin's lymphomas. Histol Histopathol 2000;15:445-453.
14. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002;100: 3935-3941.
15. Chabay P, Pesce P, De Matteo E, Lombardi MG, Rey G, Preciado MV. No Influence of bcl-2, p53, and p21waf1 protein expression on the outcome of pediatric Hodgkin lymphomas. J Pediatr Hematol Oncol 2006;28:552-558.
16. Amini RM, Berglund M, Rosenquist R, et al. A novel B-cell line (U-2932) established from a patient with diffuse large Bcell lymphoma following Hodgkin lymphoma. Leuk Lymphoma 2002;43:2179-2189.
17. Zheng B, Fiumara P, Li YV, et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: A signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003;102:1019-1027.
18. Zhang L, Ming L, Yu J. BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Update 2007;10:207-217.
19. Adams JM, Cory S. Bcl-2-regulated apoptosis: Mechanism and therapeutic potential. Curr Opin Immunol 2007;19:488-496.
20. Letai A. BH3 domains as BCL-2 inhibitors: Prototype cancer therapeutics. Expert Opin Biol Ther 2003;3:293-304.
21. Stauffer SR. Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: Proof-of-concept of an in vivo chemopotentiator ABT-737. Curr Top Med Chem 2007;7: 961-965.
22. Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 2008;111:2300-2309.
23. Lock R, Carol H, Houghton PJ, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 2007;50:1181-1189.
24. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007;12:171-185.
25. Kuroda J, Puthalakath H, Cragg MS, et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006;103:14907-14912.
26. Kline MP, Rajkumar SV, Timm MM, et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 2007;21:1549-1560.
27. Chauhan D, Velankar M, Brahmandam M, et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007;26:2374-2380.
28. Trudel S, Stewart AK, Li Z, et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 2007;13(2 Part 1):621-629.
29. Shoemaker AR, Oleksijew A, Bauch J, et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 2006;66:8731-8739.
30. Witham J, Valenti MR, De-Haven-Brandon AK, et al. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res 2007;13:7191-7198.
31. Kuroda J, Kimura S, Strasser A, et al. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ 2007;14:1667-1677.
32. Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 2007;4:1681-1689.
33. Kang MH, Kang YH, Szymanska B, et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007;110:2057-2066.
34. Narendran A, Ganjavi H, Morson N, et al. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Exp Hematol 2003;31:693-701.
35. Hawkins LM, Jayanthan AA, Narendran A. Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect toBcr-Abl status and imatinib mesylate sensitivity. Pediatr Res 2005;57:430-437.
36. Ahmed SA, Gogal RM Jr, Walsh JE. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: An alternative to 3H.thymidine incorporation assay. J Immunol Methods 1994;170:211-224.
37. Kwack K, Lynch RG. A new non-radioactive method for IL-2 bioassay. Mol Cells 2000;10:575-578.
38. Hudson L, Hay FC. (eds) The lymphocyte: Its role and function, 2nd edn. In: Practical immunology. Oxford: Blackwell Scientific Publications; 1980. pp 29-32.
39. Higurashi H, Arai M, Watanabe A, et al. Gene expression profiling of polymorphonuclear leukocytes treated with the culture filtrate of Aspergillus fumigatus and gliotoxin. Microbiol Immunol 2007;51:407-419.
40. Teruya T, Konishi T, Uechi S, Tamaki H, Tako M. Anti-proliferative activity of oversulfated fucoidan from commercially cultured Cladosiphon okamuranus TOKIDA in U937 cells. Int J Biol Macromol 2007;41:221-226.
41. Zhao L, Wientjes G, Au J. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, Isobologram and combination index analyses. Clin Cancer Res 2004;10:7994-8004.
42. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours.Nature 2005;435:677-681.
43. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10:375-388.
44. Zhang W, Konopleva M, Ruvolo VR, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008;22:808-818.
45. Yu C, Bruzek LM, Meng XW, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005;24:6861-6869.
46. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389-399.
47. Paoluzzi L, Gonen M, Bhagat G, et al. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 2008;112:2906-2916.
48. Duus J, Bahar HI, Venkataraman G, et al. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Leuk Lymphoma 2006;47:1369-1378.
49. Kutuk O, Letai A. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res 2008;68:7985-7994.
50. Chen J, Fiskus W, Eaton K, et al. Co-treatment with BCL-2 antagonist sensitizes cutaneous T cell lymphoma to lethal action of HDAC7-Nur77 based mechanism. Blood, 2008(Dec) Epub ahead of print.
51. Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-κ B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996;87: 4340-4347.
52. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997;100:2961-2969.
53. Bernal-Mizrachi L, Lovly CM, Ratner L. The role of NF-{κ} B-1 and NF-{κ}B-2-mediated resistance to apoptosis in lymphomas. Proc Natl Acad Sci USA 2006;103:9220-9225.
54. García JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: Analyses using tissue microarrays. Blood 2003;101:681-689.